"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21 that is designed to regulate key metabolic pathways to decrease liver fat, ...

Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting® ...

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks ...

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) May 14, 2025 2:14 AM ET GSK plc (GSK) ...

Efimosfermin, formerly known as BOS-580, was originally developed by Novartis. Boston Pharma licensed global rights to the asset in 2020; financial terms were not disclosed. Beyond GSK’s upfront ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis significantly improved outcomes after 24 weeks.

Together, we look forward to efimosfermin’s ongoing journey to become a best-in-class treatment for patients with SLD.” The addition of efimosfermin further strengthens GSK’s hepatology pipeline of ...